	US 12,247,204 B1
	Advanced RNA targeting (ARNATAR) for angiotensinogen
Yen Lieu, San Diego, CA (US); Lingdi Zhang, San Diego, CA (US); Xuehai Liang, San Diego, CA (US); and Yanfeng Wang, San Diego, CA (US)
Assigned to ARNATAR THERAPEUTICS, INC, San Diego, CA (US)
Filed by Arnatar Therapeutics, Inc, San Diego, CA (US)
Filed on Jun. 21, 2024, as Appl. No. 18/751,048.
Application 18/751,048 is a continuation of application No. PCT/US2024/033852, filed on Jun. 13, 2024.
Claims priority of provisional application 63/472,727, filed on Jun. 13, 2023.
Claims priority of provisional application 63/472,780, filed on Jun. 13, 2023.
Claims priority of provisional application 63/533,283, filed on Aug. 17, 2023.
Int. Cl. C12N 15/113 (2010.01); A61P 9/12 (2006.01); C07H 21/02 (2006.01)

CPC C12N 15/113 (2013.01) [A61P 9/12 (2018.01); C07H 21/02 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/351 (2013.01)]

22 Claims

1. A compound comprising an siRNA compound for inhibiting expression of angiotensinogen (AGT) in a cell, wherein the siRNA compound comprises a sense strand and an antisense strand forming a duplex, wherein the sense strand comprises SEQ ID NO: 55 and a GalNAc moiety as shown in the formula: